Stomach Cancer Is No Longer One Disease —
It's Five.
Since 2024, first-line treatment for advanced gastric cancer is no longer "chemotherapy for everyone." It is decided by five biomarkers: HER2, CLDN18.2, PD-L1 CPS, MSI/MMR, and EBV. Two patients with the identical diagnosis can receive completely different treatments — and get very different outcomes. This page is your navigation layer: understand your biology, find your line of therapy, and route to the right country.
💡 The Reality Check: Myth: "All stomach cancers are treated with the same chemotherapy, so the country doesn't matter." Reality: Gastric cancer is now molecularly divided into five treatable subgroups. A HER2-positive patient gets trastuzumab-based therapy; a CLDN18.2-positive patient can receive zolbetuximab (FDA-approved 2024) or a CLDN18.2 CAR-T trial in China; an MSI-High patient may benefit most from immunotherapy. If your pathology report does not include HER2, CLDN18.2, PD-L1 CPS, and MMR/MSI — your workup is incomplete, and you may be missing a therapy that was built for your exact tumor.
The 5-Biomarker Map
Your tumor's biology determines your first-line therapy. These five biomarkers are essential for treatment selection.
HER2
15–22% of gastric cancersTrastuzumab + chemo ± pembrolizumab — first-line. Post-trastuzumab progression → T-DXd (Enhertu).
Key Trials: ToGA, KEYNOTE-811, DESTINY-Gastric04
CLDN18.2
30–40% of gastric cancersZolbetuximab + chemo (1st line) — FDA-approved 2024. CT041 CAR-T trials in China for pretreated patients.
Key Trials: SPOTLIGHT, GLOW, CT041 Ph2/3
PD-L1 CPS
CPS≥5 in ~30%Nivolumab + chemo for CPS≥5 (CheckMate-649). Pembrolizumab + chemo for CPS≥1 (KEYNOTE-859).
Key Trials: CheckMate-649, KEYNOTE-859
MSI-H / dMMR
3–8% of gastric cancersImmunotherapy backbone — chemo benefit may be limited. Consider chemo-sparing immunotherapy strategies.
Key Trials: KEYNOTE-059, KEYNOTE-061, KEYNOTE-062
EBV-Positive
5–10% of gastric cancersExceptional immunotherapy response — highest of any subgroup. Emerging consensus data supports immune checkpoint inhibitors.
Role: Strong predictor of immunotherapy benefit
FGFR2b (Emerging)
~5% of gastric cancersBemarituzumab — emerging targeted option. Ongoing FIGHT and FORTITUDE-1 trials.
Status: Investigational, trial access
Insight: CLDN18.2 is the "new HER2" of gastric cancer — the first target since 2010 to add a targeted first-line option. China leads the world in CLDN18.2 CAR-T development. Request biomarker testing guidance →
First-Line Decision Engine
Your biomarker results determine your first-line therapy. Follow the decision tree below.
Newly Diagnosed Advanced / Metastatic Gastric or GEJ Cancer
→ 🇺🇸 USA / 🇩🇪 Germany / 🇨🇳 China
→ CLDN18.2 CAR-T (CT041) trial → 🇨🇳 China
Resistance Matrix
Every treatment fails eventually. Here's why — and what to do next.
| Failed Line | Why It Failed | Test Now | Next Option | Best Country |
|---|---|---|---|---|
| Trastuzumab + chemo | HER2 loss / intratumoral heterogeneity | Re-biopsy: HER2, CLDN18.2 | T-DXd (Enhertu) | 🇺🇸 USA / 🇩🇪 Germany |
| Chemo + IO | PD-L1 downregulation, immune escape | PD-L1 re-test, TMB | Ramucirumab + paclitaxel (RAINBOW) | 🇰🇷 Korea / 🇩🇪 Germany |
| Zolbetuximab + chemo | CLDN18.2 loss | CLDN18.2 IHC re-test | CLDN18.2 CAR-T (CT041) | 🇨🇳 China |
| Ramucirumab + paclitaxel | Angiogenesis-independent escape | NGS, FGFR2b | TAS-102 / Apatinib / FGFR2b trial | 🇨🇳 China (apatinib) / 🇺🇸 USA |
| Chemo in MSI-H | Chemo-refractory biology | Confirm MSI/MMR | Switch to immunotherapy | 🇩🇪 Germany / 🇰🇷 Korea |
| Peritoneal-only progression | Peritoneal sanctuary, poor systemic penetration | Cytology (CY), PCI score | HIPEC / PIPAC evaluation | 🇩🇪 Germany / 🇨🇳 China |
Critical Insight: Re-biopsy at progression is essential — biomarker status can change under treatment pressure. CLDN18.2 loss, HER2 loss, and PD-L1 downregulation are common resistance mechanisms that guide next-line therapy selection.
Honest Assessment: When NOT to Follow the Standard Path
Not every patient should pursue aggressive treatment. These scenarios require careful reconsideration.
Early Resectable Disease
Surgery with D2 lymphadenectomy at a high-volume center is the curative path. Do not delay surgery for trials.
Diffuse / Signet-Ring with Peritoneal Seeding
Systemic therapy alone often underperforms. Evaluate HIPEC/PIPAC and intraperitoneal chemo options early.
Triple-Negative (HER2–, CLDN18.2–, CPS<1)
Do not pay an immunotherapy premium without supporting data. Prioritize trials or palliative care.
ECOG ≥3
Aggressive combinations add toxicity without benefit. Consider best supportive care or single-agent therapy.
CancerCareE position: We will tell you when aggressive treatment is not appropriate. Request a candid assessment →
Country Logic by Biological Strength
Each country offers unique strengths for gastric cancer treatment — from CLDN18.2 CAR-T to HIPEC expertise.
China — CLDN18.2 CAR-T World Leader
CT041 CAR-T trials, apatinib approved 3rd line, sintilimab/tislelizumab access, $15K–$40K treatment costs.
Explore ChinaSouth Korea — High-Volume D2 Surgery
Robotic gastrectomy, S-1 expertise, JCI-accredited centers, high-volume surgical experience.
Explore South KoreaGermany — Zolbetuximab & HIPEC
EMA access to zolbetuximab + Enhertu, HIPEC expertise, molecular tumor boards.
Explore GermanyUSA — Enhertu, Zolbetuximab, FGFR2b
NCCN-aligned care, latest clinical trials, FDA-approved targeted therapies.
Explore USAIndia — Cost-Effective Chemo/IO & Surgery
Affordable chemotherapy and immunotherapy, high-volume surgical centers.
Explore IndiaTurkey — Strategic Hub, D2 Surgical Volume
Arabic/Persian support, D2 surgical experience, access to European protocols.
Explore TurkeyFrequently Asked Questions
Common questions about gastric cancer treatment, biomarkers, and access.
CLDN18.2 is a surface protein expressed on gastric cancer cells. Zolbetuximab + chemotherapy is FDA-approved (2024) for CLDN18.2-positive, HER2-negative advanced gastric cancer. China leads the world in CLDN18.2 CAR-T development with CT041 trials showing promising results in pretreated patients.
Yes — HER2, CLDN18.2, PD-L1 CPS, MSI/MMR, and EBV status should be tested at diagnosis. These five biomarkers determine first-line therapy selection. Starting treatment without a complete biomarker panel may mean missing a therapy specifically designed for your tumor's biology.
Ramucirumab + paclitaxel (RAINBOW trial) is the standard second-line option. For HER2-positive patients who progressed on trastuzumab, T-DXd (Enhertu) is preferred if available. In China, apatinib is approved for third-line use. Clinical trials should always be considered.
HIPEC has selective benefit in gastric cancer with peritoneal metastasis. Best candidates have: limited peritoneal spread (PCI ≤10-15), no distant metastases, good performance status, and access to a high-volume center. HIPEC is best performed in Germany or South Korea.
The best country depends on your biomarker subgroup. CLDN18.2 CAR-T → China; zolbetuximab/Enhertu → USA/Germany; high-volume D2 surgery → Korea/Germany/Turkey; cost-effective chemotherapy/immunotherapy → India. Your tumor biology should drive the country selection.
Related Decision Resources
China: CLDN18.2 CAR-T & Apatinib
CT041 CAR-T trials, apatinib 3rd-line access, and sintilimab/tislelizumab options.
View China Guide →CAR-T & Cellular Therapy
Complete guide to CAR-T therapy, including CLDN18.2-targeted trials in China.
Explore CAR-T →Clinical Trials Database
Search active gastric cancer trials by biomarker, phase, and country.
Search Trials →Cost Transparency
Real-world costs for Enhertu, zolbetuximab, CAR-T, and HIPEC across 7 countries.
View Cost Guide →Ready to Match Your Gastric Cancer to the Right Pathway?
Submit your pathology, biomarker results, and treatment history. Our oncology team analyzes your molecular profile within 48 hours — identifying the optimal first-line strategy, CAR-T trial, HIPEC center, or second-line option.
Free • Confidential • 48-Hour Response • No Obligation • HIPAA-Aligned